STOCK TITAN

Deep Track, David Kroin File 13G/A for ALLK Showing No Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Three reporting persons filed a Schedule 13G/A for Allakos Inc. (Common Stock). The filers—Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin—report zero shares beneficially owned and 0.00% ownership of the class. The statement shows no sole or shared voting or dispositive power attributed to any reporting person.

The calculation of the percentage is based on the issuer's reported share count of 90,376,972 common shares outstanding. The filing includes a joint filing statement where the undersigned agree to file future amendments on behalf of each other and confirm responsibility for their respective disclosures.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Schedule 13G/A shows the reporting group holds no economic or voting stake in ALLK, so no ownership-driven influence.

This disclosure indicates Deep Track entities and David Kroin do not currently hold, vote, or dispose of any Allakos common shares, reported as 0 shares (0.00%) based on 90,376,972 shares outstanding. For investors, the filing confirms absence of a passive ownership stake from these parties and removes potential near-term ownership-based governance influence. The joint filing clause merely allocates amendment responsibilities among the filers.

TL;DR: Governance impact is neutral—no shared or sole voting/dispositive authority is reported by these filers.

The Schedule 13G/A classifies the reporting persons with types including IA, OO, CO, HC, IN where applicable, but records zero voting and dispositive powers






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Deep Track Capital, LP
Signature:/s/ David Kroin
Name/Title:David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:08/14/2025
Deep Track Biotechnology Master Fund, Ltd.
Signature:/s/ David Kroin
Name/Title:David Kroin, Director
Date:08/14/2025
David Kroin
Signature:/s/ David Kroin
Name/Title:David Kroin
Date:08/14/2025
Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of August 14, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person The amount beneficially owned by each Reporting Person is determined based on 90,376,972 Common Stock outstanding as of May 5, 2025 according to the issuer's 10-Q filed with the SEC on May 7, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin

FAQ

Who filed the Schedule 13G/A for Allakos (ALLK)?

Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin are the reporting persons listed.

How many Allakos (ALLK) shares do the reporting persons beneficially own?

The reporting persons state they beneficially own 0 shares, representing 0.00% of the class.

What voting or dispositive powers do the filers claim for ALLK shares?

The filers report no sole or shared voting power and no sole or shared dispositive power over Allakos common stock.

What share count was used to calculate the ownership percentage for ALLK?

The percentage is calculated using the issuer's reported common share total of 90,376,972 shares outstanding.

Does the filing indicate a coordinated group or control intent for ALLK?

The filing includes a joint filing statement to manage amendment responsibilities, but reports no ownership or control by the filers.
Allakos

NASDAQ:ALLK

ALLK Rankings

ALLK Latest News

ALLK Latest SEC Filings

ALLK Stock Data

29.63M
88.59M
Research and Development in Biotechnology
Pharmaceutical Preparations
Link
US
SAN CARLOS